{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-000993","form_type":"8-K","ticker":"PIII","cik":"0001832511","company_name":"P3 Health Partners Inc.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.837543+00:00","generated_at":"2026-06-07T01:02:29.716463+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"P3 Health reaffirms 2023 guidance; 2024 revenue $1.45B-$1.55B, positive EBITDA $20M-$40M","bullets":["FY2023 reaffirmed: revenue $1.2B-$1.25B, medical margin $155M-$175M, Adj. EBITDA loss $30M-$50M.","FY2024 guidance: revenue $1.45B-$1.55B, medical margin $230M-$250M, Adj. EBITDA positive $20M-$40M.","Medicare Advantage members expected 125k-135k in 2024, up from 115k-120k in 2023.","Medical margin PMPM guided $165-$175 in 2024, up from $120-$130 in 2023.","Management expects meaningful profitability in 2024, citing robust pipeline and managed cost trend."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-000993","json":"https://secwatch.observer/filing/0001628280-24-000993.json","markdown":"https://secwatch.observer/filing/0001628280-24-000993.md","text":"https://secwatch.observer/filing/0001628280-24-000993.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832511/000162828024000993/0001628280-24-000993-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832511/000162828024000993/piii-20240109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:02:29.716463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ac513fb04c9adae4e81c8fd6ad7aedf551a000e","claim":"P3 Health Partners Inc. reported Full-Year 2024 results: revenue $1.45 billion to $1.55 billion. Guidance initiated.","evidence_excerpt":"Providing full-year 2024 guidance: • Medicare Advantage Members from 125,000 to 135,000 • Revenue from $1.45 billion to $1.55 billion • Medical Margin from $230 million to $250 million • Medical Margin PMPM from $165 to $175 • Adjusted EBITDA from $20 million to $40 million, as previously announced","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832511/000162828024000993/0001628280-24-000993-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full-Year 2024"},{"label":"Revenue","value":"$1.45 billion to $1.55 billion"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"45361cd86ba5616551e02db572c4652909226615","claim":"P3 Health Partners Inc. reported Full-Year 2023 results: revenue $1.2 billion to $1.25 billion. Guidance reaffirmed.","evidence_excerpt":"Reaffirming full-year 2023 guidance : • Medicare Advantage Members from 115,000 to 120,000 • Revenue from $1.2 billion to $1.25 billion • Medical Margin from $155 million to $175 million • Medical Margin PMPM from $120 to $130 • Adjusted EBITDA is expected to be a loss between $50 million and $30 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832511/000162828024000993/0001628280-24-000993-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full-Year 2023"},{"label":"Revenue","value":"$1.2 billion to $1.25 billion"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}